Aurora Kinase A Regulates M1 Macrophage Polarization and Plays a Role in Experimental Autoimmune Encephalomyelitis

[1]  M. Coumar,et al.  Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013) , 2014, Expert opinion on therapeutic patents.

[2]  M. Washington,et al.  Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. , 2013, Gastroenterology.

[3]  Gyula Hoffmann,et al.  Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. , 2013, Arthritis and rheumatism.

[4]  Michael J. Davis,et al.  Macrophage M1/M2 Polarization Dynamically Adapts to Changes in Cytokine Microenvironments in Cryptococcus neoformans Infection , 2013, mBio.

[5]  D. Zheleva,et al.  Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.

[6]  Jeffrey Ecsedy,et al.  The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells , 2012, Molecular Cancer Therapeutics.

[7]  N. Leitinger,et al.  Phenotypic modulation of macrophages in response to plaque lipids , 2011, Current opinion in lipidology.

[8]  H. Hsieh,et al.  Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 – 10) , 2011, Expert opinion on therapeutic patents.

[9]  H. Lockstone,et al.  IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses , 2011, Nature Immunology.

[10]  M. Biran,et al.  Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration , 2011, Multiple sclerosis.

[11]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[12]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[13]  J. Berlin,et al.  Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics? , 2010, Molecular Cancer Therapeutics.

[14]  W. Earnshaw,et al.  Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins , 2009, Current opinion in cell biology.

[15]  Feimeng Zheng,et al.  Aurora-A down-regulates IkappaBα via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival , 2009, Molecular Cancer.

[16]  G. Bottegoni,et al.  Small molecule aurora kinases inhibitors. , 2009, Current medicinal chemistry.

[17]  K. Shimada.  Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[18]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[19]  F. J. Ramos,et al.  Aurora kinase family: a new target for anticancer drug. , 2008, Recent patents on anti-cancer drug discovery.

[20]  K. Washington,et al.  Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions , 2008, Cancer.

[21]  M. Dimopoulos,et al.  Aurora kinases as targets for cancer therapy. , 2008, Cancer treatment reviews.

[22]  S. Youssef,et al.  Type II monocytes modulate T cell–mediated central nervous system autoimmune disease , 2007, Nature Medicine.

[23]  T. So,et al.  The kinases aurora B and mTOR regulate the G1–S cell cycle progression of T lymphocytes , 2007, Nature Immunology.

[24]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[25]  Ningli Li,et al.  Role of IFN-γ in induction of Foxp3 and conversion of CD4+ CD25– T cells to CD4+ Tregs , 2006 .

[26]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[27]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[28]  X. Chen,et al.  Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. , 2006, The Journal of clinical investigation.

[29]  A. Sica,et al.  Macrophage polarization comes of age. , 2005, Immunity.

[30]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[31]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[32]  L. Gosselin,et al.  Targeting the immune system to improve ventilatory function in muscular dystrophy. , 2004, Medicine and science in sports and exercise.

[33]  Marty W. Mayo,et al.  Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* , 2001, The Journal of Biological Chemistry.

[34]  E. Lees,et al.  The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation , 2000, Oncogene.

[35]  S. Sakoda,et al.  The effect of apoptosis inhibitors on experimental autoimmune encephalomyelitis: apoptosis as a regulatory factor. , 2000, Biochemical and biophysical research communications.

[36]  S Gordon,et al.  Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation , 1992, The Journal of experimental medicine.